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Abstract 36 
• Background: There are marked geographical as well as temporal differences 37 
in patient sensitization profiles to beta-lactams (BL).  38 
• Objective: To determine the utility of skin test reagents and identify a cohort 39 
of patients where skin testing can be safely omitted in a cohort of patients 40 
referred to a UK tertiary referral centre. 41 
• Methods: A retrospective study of the clinical characteristics of 1092 patients 42 
referred for BL allergy testing was analysed using multivariate regression 43 
analysis. The effectiveness of skin test reagents was also evaluated.  44 
• Results: Multivariate logistic regression identified that a history of 45 
anaphylaxis (OR 10.98, p=0.001) and the patients recall of the index drug 46 
(apart from Ampicillin and Meropenem, OR 3.51–12.43, p<0.05) were 47 
independent predictors of type I BL allergic status and a time of <1 year 48 
elapsed since index reaction significantly increasing the odds of a patient with 49 
a history of anaphylaxis, having a type I BL allergy (OR 38.66, p=0.003). An 50 
absence of anaphylactic severity, unknown name of the index drug and a 51 
reaction occurring > 1 year prior to testing, has a NPV of 98.4%, which was 52 
similar to the NPV of skin testing of 98.9% for type I BL allergy. The NPV of 53 
skin testing with benzylpenicillin + amoxicillin ± index BL was similar with 54 
(98.9%) or without (98.1%) the use of PPL and MD for type I BL allergy. 55 
• Conclusion: We identified a “low risk” cohort of patients where the history is 56 
of similar reliability to skin testing in predicting non-allergic status for BL 57 
allergy.  58 
  59 
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Highlights box 60 
 61 
1. What is already known about this topic?  62 
The vast majority of patients labelled as beta-lactam allergic can in fact 63 
tolerate these drugs. It is standard practice to skin test with penicillin allergic 64 
determinants prior to drug provocation challenge. 65 
 66 
2. What does this article add to our knowledge? 67 
History of anaphylaxis, known index drug and <1 year duration are associated 68 
with immediate beta-lactam hypersensitivity. In “low risk” patients history has 69 
a similar negative predictive value to skin testing. 70 
 71 
3. How does this study impact current management guidelines? 72 
Skin testing with benzylpenicillin + amoxicillin ± index beta-lactam prior to 73 
challenge may be sufficient in some populations. A suitably trained allergist 74 
may consider omission of skin testing in “low risk” patients following 75 
appropriate risk assessment. 76 
  77 
Keywords 78 
allergy, beta-lactam, challenge, hypersensitivity, intradermal test, penicillin, 79 
provocation, skin prick test 80 
 81 
Abbreviations 82 
95% CI 95% Confidence Interval 83 
AC   Amoxicillin-clavulanate 84 
BL  Beta-lactam 85 
BP  Benzylpenicillin 86 
DPT  Drug provocation test 87 
IDT  Intradermal test 88 
NHS  National Health Service 89 
NPV  Negative Predictive Value 90 
MD  Minor determinant, Sodium Benzylpenilloate  91 
PPL  Penzylpenicillinpolylysine 92 
PT   Piperacillin-tazobactam 93 
SPT  Skin prick test  94 
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Introduction 95 
The beta-lactam (BL) class of antibiotics are the most widely used class of antibiotics 96 
and most frequently reported drug allergy. Approximately 10% of all patients report a 97 
history of penicillin “allergy”, but up to 90% of these patients are not genuinely 98 
allergic 1. This is likely due to a combination of probable initial misdiagnosis as well 99 
as the waning of sensitivity over time 2. For example, it is well known that accurate 100 
diagnosis of drug allergy vs. viral induced exanthems is notoriously difficult. 101 
However, there are no known clinical predictors of genuine BL allergies and all 102 
suspected cases must be verified with appropriate allergy testing. The limitations in 103 
capacity and costs (as well as availability of allergists) remain a significant barrier to 104 
more comprehensive BL allergy testing 3, 4. Therefore, the availability of better clinical 105 
predictors and streamlining of diagnostic tests would be of immense benefit. 106 
A thorough investigation of suspected hypersensitivity includes history taking, skin 107 
tests (skin prick (SPT) and intradermal (IDT) tests), and drug provocation tests (DPT) 108 
5, 6
. DPT remains the “gold standard”, but application of these tests are often limited. 109 
Skin tests thus remain the mainstay of investigation, essentially performed to quantify 110 
the risk of an IgE-mediated reaction to DPT.  111 
Traditionally, most authorities advocate skin testing with the “penicillin allergenic 112 
determinants” (benzylpenicillinpolylysine (PPL) and minor determinant (MD, Sodium 113 
Benzylpenilloate)), benzylpenicillin (BP), amoxicillin and, if available, the 114 
index/suspected culprit BL to maximize sensitivity 1, 5, 6. However, the requirement of 115 
these reagents has been debated. Some authorities have upheld the importance of 116 
including both PPL and MD, while others have advocated using only PPL and BP for 117 
skin tests, followed by an amoxicillin challenge 1, 5-10. There are marked geographical 118 
and temporal differences, with data suggesting fewer patients monosensitized to PPL 119 
in Europe, and reports of declining positive skin tests in chronological American 120 
studies 8, 11, 12. These differences may result from varying prescribing practices (for 121 
example, due to differences in microbial resistance patterns or differences in 122 
prescribing semi-synthetic penicillins), selection bias in testing amongst clinicians, 123 
and alterations to patient sensitization profiles. Therefore, the optimal choice of skin 124 
testing reagents likely remains both region- and time-specific.  125 
Very few studies have examined the clinical characteristics or predictors of BL 126 
allergy. Associations with gender, atopy, age and racial differences were reported, 127 
but studies have mostly been based on patients with self-reported histories rather 128 
than confirmed genuine allergies 13-16. Furthermore studies that investigated the use 129 
of predictive models to diagnose both BL allergy and drug allergy have been shown 130 
to underperform compared to conventional allergy evaluation 17, 18. 131 
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Updated and region-specific epidemiological studies of BL allergy are therefore 132 
urgently needed to optimize modern allergy testing. In this retrospective study, we 133 
evaluated the clinical characteristics and predictors of proven BL allergy, as well as 134 
the utility of skin test reagents in a large cohort of patients referred to a UK tertiary 135 
referral centre.  136 
 137 
Methods 138 
Data Collection  139 
Medical records of all patients who were referred for and underwent BL allergy 140 
testing at Guy’s and St Thomas’ (GSTT) National Health Service (NHS) Foundation 141 
Trust, United Kingdom, between July 2010 to December 2016 were reviewed. Our 142 
centre receives referrals from all healthcare professionals in the eastern and 143 
southern counties of England. All referrals were reviewed unselectively and likely 144 
represent the population of suspected BL allergic patients referred to everyday-145 
practicing local allergists during the study period. All patients attending clinic for 146 
suspected BL allergies were offered skin testing. Clinical data extracted included: 147 
age; gender; ethnicity; index drug (i.e. the suspected BL implicated in the index 148 
reaction); symptoms of index reaction; duration between testing and index reaction; 149 
SPT, IDT (immediate and delayed); and outcomes of DPT. Patients were diagnosed 150 
with BL allergy if they had a congruent history together with positive SPT, IDT or 151 
DPT. All patients underwent SPT/IDT prior to DPT. Only immediate (type I) and 152 
delayed (type IV) hypersensitivities were recorded. Type I hypersensitivity was 153 
defined as an immediate IgE mediated reaction, manifesting as urticaria, 154 
angioedema, cardiorespiratory compromise suggestive of anaphylaxis which occurs 155 
within an hour of BL administration 6. Type IV hypersensitivity was defined as a 156 
delayed T cell mediated reaction manifesting as maculopapular exanthema and fixed 157 
drug eruptions 19. Patients who had severe cutaneous adverse reactions (i.e. 158 
Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with 159 
eosinophilia and systemic symptoms, acute generalised exanthematous pustulosis) 160 
as well as patients with suspected type II and type III reactions were not included in 161 
this study. 162 
This study was conducted as part of an approved audit within the department. The 163 
data were collected in a database that was then reviewed and checked for 164 
inconsistencies by two independent investigators. Any discrepancies were then 165 
discussed between the two independent investigators and unresolved discrepancies 166 
referred to the senior investigator for a final decision. 167 
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 168 
Beta-lactam skin testing (SPT/IDT) 169 
All patients underwent skin testing, and SPT was performed prior to IDT. All patients 170 
had skin testing performed with PPL (benzylpenicillinpolylysine 0.04mg/ml, Diater 171 
Laboratorios, Madrid, Spain), MD (sodium benzylpenilloate 0.5mg/ml, Diater 172 
Laboratorios), BP (6mg/ml, Genus Pharmaceuticals, Huddersfield, United Kingdom), 173 
and amoxicillin (25mg/ml, Ibigen Srl, Aprilia, Italy). Histamine 1.0% with Phenol 0.5% 174 
(Allergy Therapeutics, Worthing, United Kingdom) was used as positive control and 175 
Phenol 0.5% (Allergy Therapeutics) was used as negative control. 176 
If clinically indicated or if it was the index BL, selected patients would also undergo 177 
SPT/IDT with amoxicillin-clavulanate (AC, 25mg amoxicillin and 5mg clavulanic 178 
acid/ml, Sandoz, Holzkirchen, Germany), flucloxacillin (SPT: 50mg/ml, IDT: 5mg/ml;  179 
Wockhardt UK Ltd, Wrexham, United Kingdom),  piperacillin-tazobactam (PT, 200mg 180 
piperacillin and 25mg tazobactam/ml, 20mg piperacillin and 2.5mg tazobactam/ml; 181 
Wockhardt UK Ltd), cephalosporins (depending on index reaction, 2mg/ml) and 182 
meropenem (SPT 50mg/ml, IDT 5.0mg/ml; AstraZeneca UK Ltd, Luton, United 183 
Kingdom). 184 
Both SPT and IDT were read at 15 minutes as an immediate reading. A positive SPT 185 
for type I hypersensitivity was defined as a wheal ≥3 mm diameter on immediate 186 
reading. A positive IDT for type I hypersensitivity was defined as a wheal expansion 187 
of ≥3 mm from the original bleb on immediate reading 6. Delayed IDT results were 188 
read at 48 to 72 hours after skin testing. Patients were asked to send photos of the 189 
skin-testing site to our secure departmental email address. The clinician who 190 
performed the IDT reviewed the photos and, if appropriate, a diagnoses of a type IV 191 
hypersensitivity was made if the pictures showed erythema, induration, infiltration, 192 
papules and vesicles at the site of skin testing 19. If there were any doubts in the 193 
diagnosis of a type IV hypersensitivity from the photos, the patient would proceed to 194 
undergo a DPT to confirm or refute the equivocal positive delayed skin test result. 195 
Patients with positive skin tests were deemed likely genuinely allergic (therefore 196 
recommended to avoid BL) and did not proceed with subsequent DPT. An exception 197 
was if there was incongruence between skin test results and clinical history, where 198 
very cautious DPT may be offered even in positive skin test results, at the discretion 199 
of the combined decision between the Allergist and individual patient. 200 
 201 
Beta-lactam DPT 202 
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Patients with negative skin tests were invited for DPT with the same BL as per their 203 
index reaction (and if the index BL was unknown, DPT was performed with the BL 204 
most clinically relevant for the patient). All patients underwent an immediate DPT, 205 
and if negative, a delayed DPT. DPT protocols were according to GSTT trust 206 
protocols and further individualized according to each patient. For example, in 207 
patients with a history of a likely reaction to BL, DPT may be performed with 208 
sequential of doses 10%, 30% and 60% of the therapeutic dose; whereas those with 209 
an history of an unlikely reaction to a BL, DPT may be performed with a single 100% 210 
therapeutic dose. Patients who had a negative immediate reaction on immediate 211 
DPT proceeded to a delayed DPT, which was usually 50% of the daily therapeutic 212 
dose over a period of 3 days for patients with histories of an unlikely reaction, again 213 
individualized and according to GSTT trust protocols. Any immediate and delayed 214 
reactions were assessed by the patients’ respective clinicians and diagnosed 215 
accordingly. A patient who developed symptoms of urticaria, angioedema, or 216 
cardiorespiratory compromise suggestive of a severe anaphylaxis within an hour 217 
after the last dose of BL was diagnosed to have a type I BL allergy 6. A patient who 218 
developed symptoms of a maculopapular exanthema or a fixed drug eruption 219 
occurring more than an hour after DPT was diagnosed to have a type IV BL allergy 220 
19
. Patients who declined or defaulted DPT were not included in subsequent analysis. 221 
 222 
Statistical Analysis 223 
Statistical analysis was performed using IBM SPSS Statistics v24 (International 224 
Business Machines Corp., Armonk, NY, United States of America). Multivariate 225 
binary logistic regression analysis was performed. The results were used to identify 226 
characteristics of the patient history that are highly associated with BL allergy. From 227 
this we characterised a “low risk” cohort which had all of the following features: “no 228 
history of anaphylaxis to BL”, “a reaction to a BL more than 1 year prior to referral” 229 
and “patients who could not recall what the index drug was” (For further details see 230 
supplementary methods). 231 
  232 
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Results 233 
Between July 2010 to December 2016, 1096 patients were referred for and 234 
underwent BL allergy testing, 4 patients were excluded at this stage of the analysis 235 
as these patients had an incongruence between their history of presentation and skin 236 
test results and subsequently had a negative DPT. In the remaining 1092 patients 237 
the male:female ratio was 1:3.1 (32%:68%) and the median age was 48 (range: 15-238 
95) years. Sixty-six percent of patients tested were of white ethnicity; while the 239 
remaining patients tested were of Black, Middle Asian, East Asian, or mixed ethnicity. 240 
The index drug was unknown in over half of patients (i.e most patients just reported a 241 
suspected allergy to “an unknown penicillin” or BL class of antibiotic). Amoxicillin 242 
(13.8%) and AC (13.4%) were the most commonly specifically implicated penicillin-243 
based/BL antibiotics (Table 1). 244 
Thirty-three percent of patients presented with a history of non-specific rash, while 245 
over 25% of patients presented with urticaria and/or angioedema. Only 5% of our 246 
cohort presented following anaphylaxis (defined as 2 or more organ systems 247 
involved 20). The vast majority of patients (97.8%) were referred more than a year 248 
following the index reaction, while a minority were referred within a year of the index 249 
reaction (1.3%). 250 
Please refer to Figure 1 for a summary of our patient diagnostic pathway and 251 
outcomes. Only 122 (11.2%) patients referred for allergy testing were finally 252 
diagnosed with highly-suspected/confirmed BL allergy – patients with positive skin 253 
test results did not undergo subsequent DPT due to high risk. Eighty-three (7.6%) 254 
patients had an immediate-type (type I) hypersensitivity and 39 (3.6%) had delayed-255 
type (type IV) hypersensitivies. Three additional patients were diagnosed with a 256 
delayed hypersensitivity to clavulanic acid. These 3 patients had positive delayed 257 
IDT to AC but negative to amoxicillin; and all 3 had a subsequent negative DPT with 258 
amoxicillin. 259 
Of the 122 suspected/confirmed BL allergies, 96 (78.6%) were diagnosed by skin 260 
testing (74 [60.7%] immediate, 22 [18.0%] delayed), while 26 (21.3%) were 261 
confirmed by DPT (9 [7.4%] immediate, 17 [13.9%] delayed). Of note, none of the 262 
positive DPT suffered anaphylaxis and none required treatment with adrenaline 263 
(Table 2). All patients who had a negative skin test were invited for DPT, 797 patients 264 
attended for challenges while 199 patients did not undergo DPT. 265 
The initial multivariate logistic regression (Table 3, Model 1) identified that the 266 
variables, history of reaction (p < 0.001), time of reaction (p = 0.004) and index drug 267 
(p = 0.001) were independently and significantly associated with type I BL allergy. 268 
While patients with a history of anaphylaxis (OR 38.67, 95% CI 13.26 – 112.89, p < 269 
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0.001) were 39 times more likely to have a type I BL allergy compared to those with 270 
other symptoms, those with cutaneous symptoms only were not (OR 1.26, 95% CI 271 
0.57 – 2.80, p = 0.564). Furthermore if a patient could recall what their index BL was 272 
(apart from Meropenem) they were 4 to 15 times more likely to have a type I BL 273 
allergy compared to those who could not recall their index BL (OR 3.97 – 14.78, p < 274 
0.05). Patients with <1 year elapsed since index reaction were 2.5 times more likely 275 
to have a type I BL allergy compared to those with >1 year elapsed since index 276 
reaction (OR 2.69, 95% CI 1.38 – 5.23, p = 0.004). 277 
An improved multivariate logistic regression model was constructed with the inclusion 278 
of the variable history of reaction less than 1 year ago (Table 3, Model 2). In the final 279 
model history of reaction (p = 0.004), index drug (p = 0.001) and history of reaction 280 
less than 1 year ago (p = 0.001) were independently and significantly associated with 281 
type I BL allergy. Patients with a history of anaphylaxis (OR 10.98, 95% CI 2.58 – 282 
46.76, p = 0.001), those who could recall what their index BL was (apart from 283 
Ampicillin and Meropenem, OR 3.51 – 12.43, p < 0.05), and a reaction <1 year ago, 284 
particularly in patients with a history of anaphylaxis (OR 38.66, 95% CI 3.46 – 285 
432.13, p = 0.003) was associated with increased odds of type I BL allergy. 286 
We characterised a “low risk” cohort which had all of the following features in the 287 
patient history: “no history of anaphylaxis to BL”, “a reaction to a BL more than 1 year 288 
prior to referral” and “patients who could not recall what the index drug was”. The 289 
NPV of the history at presentation for a type I hypersensitivity reaction with the 3 290 
characteristic traits of the “low risk” cohort was 98.4% (n= 493, 95% CI 97.2% – 291 
99.4%) which is similar to the NPV of skin testing for a type I hypersensitivity reaction 292 
in the whole cohort of 98.9% (95% CI 98.1 – 99.5%). Of note the NPV of the history 293 
for BL allergy in the cohort of patients classified as not “low risk” (i.e. the entire cohort 294 
excluding the “low risk” cohort) was 80.6% (95% CI 76.9 – 84.6%). For the low risk 295 
cohort, 1% (95% CI 0.2% – 1.9%) of patients had a positive immediate skin test 296 
reading, 1.6% (95% CI 0.6% – 2.8%) of patients had a positive delayed skin test 297 
reading, 0.6% (95% CI 0.0% – 1.4%) of patients had a positive immediate DPT, while 298 
1.8% (95% CI 0.8% – 3.2%) of patients had a positive delayed DPT.  299 
The index drug was unknown in the majority of referrals (56.8%) as neither the 300 
patient nor the referring clinician was able to provide the name of the drug involved in 301 
the index reaction. For the remaining patients, amoxicillin or AC were the most 302 
frequently suspected culprit with a frequency of approximately 4 times more than BP 303 
(the second most frequent) and 7 times more than flucloxacillin (the third most 304 
frequent) (Table 1).  305 
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Of 74 patients who had an immediate reaction on skin testing, 80% of patients tested 306 
positive to amoxicillin. Almost half (48%) of patients were monosensitized to 307 
amoxicillin while 70% of patients had a negative skin test to both PPL and MD. The 308 
diagnosis of immediate hypersensitivity by skin testing could be made in 92% of 309 
patients with the utilization of only BP + amoxicillin ± index BL (i.e. without the need 310 
for PPL and MD). The utilization of only BP + amoxicillin ± index BL for skin testing is 311 
estimated to have a NPV for a type I hypersensitivity reaction of 98.1% (95% CI 312 
97.1% – 99.0%), a reduction of approximately 1% when compared to the NPV for 313 
skin testing with PPL + MD + BP + amoxicillin ± index BL which is 98.9% (95% CI 314 
98.1 – 99.5%). 315 
  316 
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Discussion 317 
In our cohort we identified that a historical reaction of anaphylaxis, knowing the index 318 
drug and a reaction <1 year ago, particularly in patients with a history of anaphylaxis, 319 
were associated with a type I beta-lactam hypersensitivity. Furthermore, in patients 320 
who have no history of anaphylaxis, and a reaction of > 1 year from presentation, 321 
who are unable to recall the index drug, the NPV of the history is similar to that of 322 
skin testing, with 1% of these patients having a positive immediate skin tests and 323 
0.6% having a positive immediate DPT in this “low risk” cohort.  We also found in our 324 
cohort that including the penicillin allergenic determinants (PPL and MD) for skin 325 
testing, in comparison to the use of BP + amoxicillin ± index BL did not significantly 326 
affect the NPV of skin testing for our cohort.  327 
A historical reaction of anaphylaxis was significantly more common in patients with 328 
immediate-type hypersensitivity. This resonates with our clinical observation that the 329 
patients presenting with anaphylaxis following BL administration are more likely to 330 
have a positive DPT and/or positive SPT/IDT. This may reflect the objectivity and 331 
higher specificity of anaphylactic reactions for true IgE-mediated responses in 332 
comparison to other manifestations. Patients with positive skin testing or DPT were 333 
more likely to be aware of the index BL and presented for investigation within a year 334 
since their reaction. This is supported by previous reports of BL sensitivity waning 335 
over time 2. While these associations may be due to referral bias or underlying 336 
correlations with reaction severity (attending clinicians and patient may refer earlier 337 
and be more aware of the index BL); nonetheless, ascertaining these parameters 338 
during history taking will aid the allergist in pre-test evaluation and clinical decision 339 
making. Our data provides further evidence that history with predictive models is 340 
unable to completely replace conventional allergy testing for BL allergy 17, 18. Our 341 
NPV of the history for BL allergy in the rest of the cohort of patients (i.e. the entire 342 
cohort excluding the “low risk” cohort) was 80.6% which is comparable to the models 343 
used by Chiriac et at.18 whose models had NPVs between 81 to 83% and that of 344 
Hierro Santurino et al17 whose model had a NPV of 84%. For our “low risk” cohort 345 
however the NPV of the history at presentation for a type I hypersensitivity reaction 346 
was 98.4% which is similar to that of skin testing in our cohort of 98.9%. Our results 347 
imply that skin testing in our “low risk” cohort does not significantly alter the risk 348 
benefit ratio of DPT above that of history. However in view of the low prevalence of 349 
severe anaphylaxis in our cohort, we are unable to ascertain from our data whether 350 
patients in the “low risk” cohort are at lower or higher risk of developing severe 351 
anaphylaxis during DPT. A suitably trained allergist could therefore consider with due 352 
caution the omission of skin testing from this “low risk” cohort of patients prior to 353 
DPT. 354 
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We found that only 4%, 1% and 3% of our BL allergic patients were solely sensitized 355 
to PPL, MD and PPL+MD, respectively. Almost half (48%) of patients with positive 356 
skin tests were monosensitized to amoxicillin (Figure 2). This low level of 357 
sensitization to PPL and MD is similar to previous reports from smaller European 358 
cohorts 12, 21, 22. These findings likely reflect the specific prescribing practices in the 359 
UK, with amoxicillin and AC being the most commonly prescribed BL in England 360 
between 2006 to 2016, with around 13-17 million prescriptions per year 361 
(approximately 6 times that for BP and 4 times that for flucloxacillin) 23. Our results 362 
are comparable to previous studies showing a very high positive aminopenicillin 363 
allergy testing rate in Europe, where amoxicillin use is higher, 2, 24, 25 suggesting 364 
regional/geographic differences in pattern of sensitivity to the major and minor 365 
determinants compared to the United States of America. This regional variability in 366 
response rates to penicillins other than the minor and major determinants has also 367 
be highlighted in studies in Kuwait and Canada 26-28. We postulate that most of our 368 
BL allergic patients were sensitized to amoxicillin, rather than natural penicillins, 369 
leading to a lower rate of sensitization to PPL and MD. However, as amoxicillin skin 370 
test/DPT positive patients did not undergo DPT with other BL, the role of side chain 371 
sensitization remains to be further investigated. 372 
The availability of penicillin allergenic determinants are still major restrictions to BL 373 
allergy testing. In our cohort, the omission of PPL and MD from the standard SPT 374 
and IDT reduced the NPV by approximately 1 percentage point to an NPV of 98.1%. 375 
The omission of PPL and MD in our cohort of patients would results in 6 out of 1092 376 
patients (1 in 182 patients) testing negative on skin test who would otherwise test 377 
positive with the utilisation of PPL and MD. Evidence from a large review paper from 378 
the United States of America suggests that using the minor and major determinants 379 
in detecting penicillin allergy has a NPV of 97% 29. This reflects the geographical 380 
variability and therefore in areas of low prevalence of BP usage and allergy (i.e. the 381 
United Kingdom/Europe), the use of determinants could be considered less 382 
beneficial and the practicing allergist could potentially omit them. However, in cases 383 
of anaphylaxis or higher BP allergy prevalence (i.e the United States of America) 384 
then omitting would be less desirable. Overall however, we strongly recommend that 385 
any decision to omit the major and minor determinants should only be made by a 386 
suitably qualified allergist who understands cohort prevalence data, geographical 387 
variability and awareness of risk stratification for penicillin allergy testing.  388 
The 8% of patients detected by major and minor determinant testing in our cohort 389 
translates to a low frequency of patients who have a positive DPT despite a negative 390 
skin test in view of the low prevalence of BP clinical allergy and general usage in the 391 
United Kingdom and Europe. Geographical variability therefore has a significant 392 
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impact on penicillin allergy prevalence data and thus would impact skin testing 393 
methodology, practice and sensitization pattern 29. Therefore the omission of major 394 
and minor determinants from standard testing is based on a population’s low 395 
prevalence of BP usage and allergy and conversely higher prevalence rates of 396 
amoxicillin usage and allergy. The major and minor determinants are being replaced 397 
with BP, amoxicillin and the index drug. It is important to note that there is published 398 
data indicating that more severe BL allergies are due to the minor determinants 29 399 
and that amoxicillin allergy is less likely to cause a severe allergic reaction 30, 31. 400 
Therefore in cases where prevalence of BP allergy is higher or there is a strong 401 
history of anaphylaxis, the use of major and minor determinants would be 402 
recommended. The allergist may consider skin testing with BP, amoxicillin and index 403 
agents only, in situations where there is a lack of availability of the major and minor 404 
determinants. The consideration of the geographical variability of penicillin allergy 405 
and sensitization patterns, as well as the ability to consistently mix the reagents 406 
(which are pharmaceutical grade licensed medications) is important to be weighed in 407 
this decision. A suitability-qualified allergist must interpret this with awareness of the 408 
prevalence data of BL allergy to have appropriate risk stratification. 409 
Our data also indicates that in “low risk” patients skin testing may be omitted prior to 410 
DPT, which is the gold standard for establishing a diagnosis of tolerance to 411 
penicillins. Especially in populations where skin testing capacity is limited, this may 412 
translate to a greater number patient that can be evaluated without compromising 413 
diagnostic accuracy (as all patients will undergo DPT). Prospective studies are 414 
therefore required to confirm our findings that may be beneficial to patient care. 415 
The main limitations of this retrospective study stem from the limitation of medical 416 
records review. Certain variables such as demographics, duration since reaction and 417 
index reactions were not available for every patient. Following a negative skin test, 418 
199 declined DPT despite invitation and therefore allergy could not confidently 419 
excluded. Retrospective data collection also includes potential referral or selection 420 
bias; for example, referring clinicians may tend to refer patients with more severe 421 
reactions or not refer patients with clear-cut histories of genuine BL allergies. 422 
Furthermore, patients who defaulted their clinic appointments or declined skin testing 423 
were not included. The variable “time of reaction” could only be categorized into <1 424 
year or ≥1 year due to limitations of medical records. This highlights the necessity of 425 
future prospective studies. Furthermore, patients with skin tests showing 426 
monosensitization to amoxicillin did not undergo DPT and we could not ascertain if 427 
they were genuine selective responders to amoxicillin (rather than false negative 428 
results with other reagents). We are planning future studies into this selective cohort 429 
of patients. More importantly, results from our cohort are region-specific and likely 430 
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pertain to local prescribing practices and sensitization profiles. Therefore, in 431 
populations with high prevalence of BL allergy, skin testing should always be 432 
performed prior to DPT irrespective of the history. Of note in patients with ‘low risk’ 433 
features the risk of anaphylaxis during DPT is not completely absent. Thus, omission 434 
of skin testing prior to DPT in patients with ‘low risk’ features should be only 435 
performed in a specialist centre with staff trained to recognize and treat allergic 436 
reactions, as well as weigh the risk benefit ratio of the omission of skin testing. We 437 
encourage further studies to corroborate the external validity of our findings. Lastly, 438 
all allergological investigations were performed by trained allergy nurses or 439 
specialists only and our results may not be directly translatable to non-allergists 440 
performing the same investigations.   441 
In conclusion, we identified that an historical reaction of anaphylaxis, knowing the 442 
index drug, and a history of anaphylaxis or cutaneous symptoms less than 1 year 443 
ago were independently associated with beta-lactam hypersensitivity. We have 444 
identified a cohort of patients who are “low risk” whose NPV of history is similar to 445 
that of skin testing, and in these patients the omission of skin testing prior to DPT 446 
may not significantly change the risk benefit ratio of DPT. Furthermore in populations 447 
with a low background prevalence of PPL and MD sensitization, the use of BP + 448 
amoxicillin ± index BL for skin testing, prior to DPT, maybe adequate to risk stratify 449 
DPT. Nevertheless, when the prevalence of BL allergy in a region is high, a detailed 450 
history followed by skin testing and DPT, if appropriate, should be always performed.  451 
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Tables 571 
 
Whole 
cohort 
Allergic Not 
Allergic Type I Type IV 
n (%) n (%) n (%) n (%) 
Total patients 1092 83 39 767 
Male 358 (32.8) 21 (25.3) 11 (28.2) 285 (37.2) 
Age in years (median, range) 48 (15-95) 53 (17-94) 46 (18-92) 49 (15-95) 
Ethnicity    
  White 718 (65.8) 51 (61.4) 25 (64.1) 529 (69.0) 
  Black 69 (6.3) 4 (4.8) 4 (10.3) 44 (5.7) 
  Middle Asian 21 (1.9) 2 (2.4) 0 (0) 17 (2.2) 
  Mixed 18 (1.6) 0 (0) 0 (0) 6 (0.8) 
  East Asian 13 (1.2) 1 (1.2) 0 (0) 7 (0.9) 
  Unknown 253 (23.2) 25 (30.1) 10 (25.6) 164 (21.4) 
Index reaction    
  Anaphylaxis 54 (4.9) 37 (44.6) 0 (0) 12 (1.6) 
  Cutaneous symptoms only 654 (59.9) 36 (43.4) 28 (71.8) 461 (60.1) 
  Others / unknown 384 (35.2) 10 (12.0) 11(28.2) 294 (38.3) 
Index beta-lactam    
  Penicillin V / G 80 (7.3) 4 (4.8) 2 (5.1) 56 (7.3) 
  Amoxicillin 151 (13.8) 22 (26.5) 6 (15.4) 88 (11.5) 
  Amoxicillin-clavulanate 146 (13.4) 36 (43.4) 9 (23.1) 70 (9.1) 
  Flucloxacillin 44 (4.0) 4 (4.8) 4 (10.3) 24 (3.1) 
  Cephalosporins 29 (2.7) 2 (2.4) 1 (2.6) 14 (1.8) 
  Piperacillin-tazobactam 13 (1.2) 3 (3.6) 0 (0) 8 (1.0) 
  Ampicillin 5 (0.5) 1 (1.2) 0 (0) 4 (0.5) 
  Meropenem 4 (0.4) 0 (0) 0 (0) 2 (0.3) 
  Unknown 620 (56.8) 11 (13.3) 17 (43.6) 501 (65.3) 
Duration since reaction    
  <1 year 14 (1.3) 53 (63.9) 7 (17.9) 106 (13.8) 
  ≥ 1 year 1068 (97.8) 30 (36.1) 32 (82.1) 651 (84.9) 
  Unknown 10 (0.9) 0 (0) 0 (0) 10 (1.3) 
 572 
Table 1: Demographics, clinical features and outcomes of 1092 patients referred for 573 
penicillin allergy testing from July 2010 to December 2016.  574 
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Age/Sex Index Drug Provocation Drug (Doses) Reaction Treatment 
1 52/F Amoxicillin Amoxicillin 50mg, 150mg Pruritis, Urticaria 
Cetirizine 
Prednisolone 
2 68/M Unknown Flucloxacillin 50mg, 150mg 
Pruritis, Urticaria, 
Angioedema 
Cetirizine 
Prednisolone 
3 26/F Penicillin V Penicillin V 50mg, 150mg Pruritis, Urticaria 
Cetirizine 
Prednisolone 
4 70/M Unknown Amoxicillin 50mg, 150mg 
Pruritis, 
Angioedema 
Cetirizine 
Prednisolone 
5 65/F Penicillin V Penicillin V 50mg, 150mg Pruritis, Urticaria 
Cetirizine 
Prednisolone 
6 43/F Amoxicillin-clavulante 
Amoxicillin-clavulante 
50mg, 150mg, 300mg Pruritis, Urticaria 
Cetirizine 
Prednisolone 
7 27/F Unknown Penicillin V 50mg, 150mg Pruritis, Urticaria 
Cetirizine 
Prednisolone 
8 48/F Unknown Amoxicillin 50mg, 150mg 
Pruritis, 
Angioedema 
Cetirizine 
Prednisolone 
9 18/F Amoxicillin Amoxicillin 50mg, 150mg, 300mg Pruritis, Urticaria 
Cetirizine 
Prednisolone 
10 29/F Amoxicillin Amoxicillin  250mg TDS for 1 day 
Maculopapular 
rash 
Cetirizine 
Prednisolone 
11 70/M Penicillin V Penicillin V  250mg QDS for 1 day 
Maculopapular 
rash 
Cetirizine 
Prednisolone 
12 41/M Amoxicillin-clavulante 
Amoxicillin-clavulante 
375mg TDS for 1 day 
Maculopapular 
rash 
Cetirizine 
Prednisolone 
13 60/F Unknown Amoxicillin  250mg TDS for 3 days 
Maculopapular 
rash 
Cetirizine 
Prednisolone 
14 37/F Amoxicillin-clavulante 
Amoxicillin-clavulante 
375mg TDS for 3 days 
Maculopapular 
rash 
Cetirizine 
Prednisolone 
15 33/F Unknown Penicillin V  250mg QDS for 2 day 
Maculopapular 
rash 
Cetirizine 
Prednisolone 
16 31/F Amoxicillin-clavulante 
Amoxicillin-clavulante 
375mg TDS for 1 day 
Maculopapular 
rash 
Cetirizine 
Prednisolone 
17 39/F Unknown Amoxicillin  250mg TDS for 3 days 
Maculopapular 
rash 
Cetirizine 
Prednisolone 
18 76/F Unknown Amoxicillin-clavulante 375mg TDS for 1 day 
Maculopapular 
rash 
Cetirizine 
Prednisolone 
19 31/F Amoxicillin Amoxicillin  250mg TDS for 3 days 
Maculopapular 
rash 
Cetirizine 
Prednisolone 
20 64/F Unknown Amoxicillin  250mg TDS for 2 days 
Maculopapular 
rash 
Cetirizine 
Prednisolone 
21 77/F Penicillin V Penicillin V  250mg QDS for 1 day 
Maculopapular 
rash 
Cetirizine 
Prednisolone 
22 46/F Unknown Flucloxacillin  250mg QDS for 3 days 
Maculopapular 
rash 
Cetirizine 
Prednisolone 
23 46/F Unknown Amoxicillin  250mg TDS for 3 days 
Maculopapular 
rash 
Cetirizine 
Prednisolone 
24 42/F Amoxicillin-clavulante 
Amoxicillin-clavulante 
375mg TDS for 1 day 
Maculopapular 
rash 
Cetirizine 
Prednisolone 
25 52/F Unknown Amoxicillin  250mg TDS for 3 days 
Maculopapular 
rash 
Cetirizine 
Prednisolone 
26 51/M Unknown Amoxicillin  250mg TDS for 3 days 
Maculopapular 
rash 
Cetirizine 
Prednisolone 
 575 
Table 2: Clinical features and outcomes of a patients who had a positive drug 576 
provocation test. (TDS = Three times a day, QDS = Four times a day)  577 
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 578 
  
95% Confidence 
Interval of Odds Ratio  
Variable Odds Ratio Lower Upper p-value 
Model 1a 
    
Age 1.02 1.00 1.04 0.07 
History of reaction    < 0.01 
Cutaneous symptoms only 1.26 0.57 2.80 0.56 
Anaphylaxis 38.67 13.26 112.89 < 0.01 
<1 year since reaction 2.69 1.38 5.23 < 0.01 
Index drug    < 0.01 
Amoxicillin 7.40 3.23 16.97 < 0.01 
Penicillin V/G 3.97 1.17 13.53 0.03 
Flucloxacillin 4.59 1.14 18.42 0.03 
Cephalosporin 8.21 1.15 58.88 0.04 
Piperacillin-Tazobactam 14.78 2.66 81.96 < 0.01 
Ampicillin 11.39 1.07 121.18 0.04 
Meropenem 0.00 0.00  1.00 
Hosmer and Lemeshow 0.04 Nagelkerke R2 0.46 
  
Model 2b     
Age 1.02 1.00 1.04 0.86 
History of reaction    < 0.01 
Cutaneous symptoms only 1.16 0.50 2.71 0.73 
Anaphylaxis 10.98 2.58 46.76 < 0.01 
Index drug    < 0.01 
Amoxicillin 6.37 2.82 14.39 < 0.01 
Penicillin V/G 3.51 1.05 11.78 0.04 
Flucloxacillin 4.23 1.05 17.03 0.04 
Cephalosporin 9.36 1.53 57.29 0.02 
Piperacillin-Tazobactam 12.43 2.21 69.96 < 0.01 
Ampicillin 9.90 0.95 103.53 0.06 
Meropenem 0.00 0.00  1.00 
History less than 1 year ago    < 0.01 
Cutaneous symptoms less 
than 1 year ago 2.60 1.23 5.48 0.01 
Anaphylaxis less than 1 year 
ago 38.66 3.46 432.13 < 0.01 
Hosmer and Lemeshow 0.06 Nagelkerke R2 0.48 
  
a
 Variables entered on step 1 were age, gender, ethnicity, time of reaction (<1 
year since reaction), history of reaction and index drug 
b
 Variables entered on step 1 were age, gender, ethnicity, time of reaction (<1 
year since reaction), history of reaction, index drug, and history of reaction less 
than 1 year ago 
 579 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 22
Table 3: Multivariate logistic regression (backward stepwise) of predictors associated 580 
with type I beta-lactam hypersensitivity.  581 
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Figure Legends 582 
 583 
Figure 1: Flow diagram of patient diagnostic pathway and outcomes (please refer to 584 
text for breakdown of skin and provocation test results). 585 
 586 
Figure 2: Edward-Venn diagram showing distribution sensitization pattern in positive 587 
skin tests. Values represent percentages. PPL – benzylpenicillinpolylysine, MD -588 
minor determinant (MD). 589 
 590 
 591 
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ACCEPTED MANUSCRIPTSuspected beta­lactam HSR:
1092 patients
Positive SPT / IDT:
99 patients
Negative SPT / IDT:
993 patients
Did not complete DPT:
199 patients
DPT performed:
797 patients
Positive DPT:
26 patients
Positive DPT (Immediate):
9 patients
Positive DPT (Delayed):
17 patients
Negative DPT:
771 patients
Positive SPT/IDT
(Immediate):
74 patients
Positive IDT (Delayed):
22 patients
(Suspected / Confirmed)
Type I HSR:
83 patients
(Suspected / Confirmed)
Type IV HSR:
39 patients
No HSR:
767 patients
Suspected Type IV HSR to clavulanic
acid: 3 patients 
Proceeded to cephalosporin DPT: 
4 patients 
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 2 
Statistical Analysis 3 
A multivariate binary logistic regression analysis was performed on our cohort of 4 
patients. 199 patients who had negative skin prick testing who defaulted challenge 5 
(lost to follow-up or decline DPT after consent), 10 patients who had unknown 6 
history, index drug and time of reaction and 4 patients who were challenged with a 7 
cephalosporin were excluded from the regression analysis. Multivariate binary 8 
logistic regression analysis was performed on the remaining cohort of 879 patients, 9 
using Enter, Forward Stepwise and Backward Stepwise regression, with type I 10 
hypersensitivity status as the dependent variable.  The independent variables 11 
entered into the regression were age, gender, ethnicity, time of reaction, history of 12 
reaction and index drug. The reference used for gender was male and the history of 13 
<1 year since reaction for time of reaction. Ethnicity was entered as a 6-category 14 
variable (white, black, middle Asian, mixed, east Asian and unknown) with white as 15 
the reference category. History of reaction was entered as a 3-category variable 16 
(anaphylaxis, cutaneous symptoms only and other symptoms) with unknown as the 17 
reference category. Index drug was entered as an 8-category variable (amoxicillin, 18 
penicillin V/G, flucloxacillin, cephalosporin, piperacillin-tazobactam, ampicillin, 19 
meropenem and unknown) with unknown as the reference category. For the history 20 
of reaction, anaphylaxis was defined as 2 or more organ systems involved E1, 21 
cutaneous symptoms only was defined as either a non specific rash, maculopapular 22 
rash or urticaria/angioedema, while other symptoms were defined as either 23 
gastrointestinal, neurological, musculoskeletal symptoms or unknown symptoms. 24 
Backward stepwise regression had the highest Nagelkerke R2 value and was 25 
selected as the regression method used.  26 
The variables entered on step 1 of Model 1 were age, gender, ethnicity, time of 27 
reaction (<1 year since reaction), history of reaction and index drug. The variables 28 
age, gender, and ethnicity failed to reach statistical significance. This model despite 29 
accounting for 46% of the variance of type I BL allergic status (Nagelkerke R2 0.460) 30 
had a poor goodness of fit (Hosmer and Lemeshow test p = 0.035). To improve 31 
goodness of fit the variable history of reaction less than 1 year ago was added to the 32 
model, and was entered as a 2-category variable (history of anaphylaxis less than 1 33 
year ago and cutaneous symptoms less than 1 year ago). The variables entered on 34 
step 1 of Model 2 were age, gender, ethnicity, time of reaction (<1 year since 35 
reaction), history of reaction, index drug, and history of reaction less than 1 year ago. 36 
Backward stepwise regression was performed and this resulted in a model which 37 
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accounted for 48% of the variance of type I BL allergic status (Nagelkerke R2 0.479) 38 
with an acceptable goodness of fit (Hosmer and Lemeshow test p = 0.062). 39 
Regression analysis including the following variables “index drug less than 1 year 40 
ago”, “history of reaction due to an index drug” and “history of reaction due to an 41 
index drug less than 1 year ago” were all not statistically significant and did not 42 
improve goodness of fit (data not shown). 43 
Data were summarised as percentages and frequencies where appropriate. Data 44 
were compared using the Chi-squared test and statistical significance set at p < 0.05. 45 
Edwards’ Venn diagram was generated using the web-based application jvenn E2. 46 
Bootstrapping was performed and 95% confidence intervals are based on 1000 47 
bootstrap samples.  48 
 49 
 50 
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